Dr. Curtis P Swagler, D.O. General Practice Medicare: Not Enrolled in Medicare Practice Location: Eisenhower Drive, Rm 422 Student Health Center, University Park, PA 16802 Phone: 814-863-6747 Fax: 814-863-8464 |
News Archive
MarketResearch.com has announced the addition of Kalorama Information's new report, "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets," to their collection of Healthcare market reports.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.
The global epidemic of Type 2 diabetes is an indicator of serious underlying issues in our society, says a University of Sydney medical expert.
Elizabeth Hopkins, an aspiring physician and pre-medical student in the Charles E. Schmidt College of Science at Florida Atlantic University, has spent more than 640 hours shadowing Hilton Becker, M.D., a local plastic and reconstructive surgeon, and an affiliate professor in FAU's Charles E. Schmidt College of Medicine. Together, with Jeffrey Lind II, M.D., they authored a publication in the current issue of Plastic and Reconstructive Surgery Journal, which describes a revolutionary procedure developed by Becker that is an alternative to radical mastectomy.
In its recently released annual 2010 update, ChartTrendsĀ®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc. finds that newer biologic agents such as UCB's Cimzia and Centocor OrthoBiotech's Simponi, although lagging in overall market share, have begun to penetrate the first line biologic position primarily at the expense of Pfizer/Amgen's Enbrel and Abbott's Humira.
› Verified 9 days ago